HOYA Vision Care Releases Results of Three-Year MiYOSMART Spectacle Lens Follow-up Study.

HOYA Vision Care shared the results of a three-year follow-up clinical study on its award winning MiYOSMART spectacle lens with patented Defocus Incorporated Multiple Segments (D.I.M.S.) Technology after releasing the information at the recent European Academy of Optometry and Optics (EAOO) ’21 conference.

The new study, published in March 2021 in the British Journal of Ophthalmology (1), was conducted by the Centre for Myopia Research at The Hong Kong Polytechnic University and followsup on the two-year study which previously demonstrated evidence of the effectiveness of the lens in slowing down the progression of myopia in children ages 8-131 .

The three-year follow-up study, conducted on 120 children in Asia, included 65 from the original group using MiYOSMART lens who took part in the previous study and 55 children who moved from using a single-vision lens for two years to the MiYOSMART lens in the third year.

At the end of the third year, results in the original group of children using them showed that slowing in myopia progression over time was sustained and the group that moved from regular single-vision to MiYOSMART spectacle lens showed a significant and immediate slow-down in the progression of myopia.

Launched in some markets in mid-2018, the MiYOSMART spectacle lens was developed in cooperation with The Hong Kong Polytechnic University to address myopia, or near sightedness which is a growing global health concern with industry experts predicting nearly 50% of the world’s population to be impacted by 2050.

The lens uses patented D.I.M.S. Technology that provides children with sharp vision, can be placed in any children’s eyeglass frame and appears as a regular lens. Based on the three-year follow-up study, the MiYOSMART lens can slow and in some cases halt myopia progression by utilizing myopic defocus.

(1). Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomized clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.1136/bjophthalmol-2018-313739

PRODUCT DISCLAIMER – MiYOSMART has not been approved for myopia management in all countries, including the U.S., and is not currently available for sale in all countries, including the U.S.


Top